SPPI
$0.95
Spectrum Pharma
($.06)
(5.94%)
SPPI
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.22)
Revenue:  $0.00 Mil
Wednesday
Feb 9
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SPPI reports earnings?
Beat
Meet
Miss

Where is SPPI's stock price going from here?
Up
Flat
Down
Stock chart of SPPI
Analysts
Summary of analysts' recommendations for SPPI
Score
Grade
Pivots
Resistance
$1.09
$1.05
$1.00

$0.97

Support
$0.92
$0.88
$0.83
Tweet
Growth
Description
Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease.
Peers
Vertex PharmaceuticalsMerck & Co.Ultragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisEli LillyPfizerInterCept